BioCentury | Mar 11, 2019
Clinical News

Axovant reports first clinical gene therapy data

...AXO-Lenti-PD and ProSavin are each lentiviral gene therapies designed to deliver three genes -- TYH, GCH1...
...was up 3.40p to 713.30p on Monday. Targets: DDC (AADC) - Dopa decarboxylase; GCH1 - GTP cyclohydrolase 1...
...B; TYH - Tyrosine hydroxylase Sandi Wong, Staff Writer AXO-AAV-GM2 AXO-Lenti-PD, OXB-102 Sio Gene Therapies Inc. Dopa decarboxylase (DDC) (AADC) GTP cyclohydrolase 1 (GCH1) Hexosaminidase...
BioCentury | Dec 1, 2017
Company News

Neuropathic pain company Quartet ending operations

...28-day toxicology study" for one of its lead programs. Quartet was developing inhibitors of GTP cyclohydrolase 1 (GCH1...
BioCentury | Nov 17, 2017
Company News

Neuropathic pain company Quartet ending operations

...28-day toxicology study" for one of its lead programs. Quartet was developing inhibitors of GTP cyclohydrolase 1 (GCH1...
...31. Koenig is also an advisor at Atlas. Chris Lieu Atlas Venture Merck & Co. Inc. Quartet Medicine Inc. GTP cyclohydrolase 1 (GCH1) Sepiapterin...
BioCentury | Nov 10, 2014
Emerging Company Profile

Quartet: Orchestrating pain relief

...is investigating inhibitors of two key enzymes in the BH4 de novo synthesis pathway: GTP cyclohydrolase 1 (GCH1...
...the final conversion step in the pathway. Pojasek said rat data have shown that inhibiting GCH1...
...on these findings, Quartet raised $17 million in a series A round to get a GCH1...
BioCentury | Oct 24, 2014
Financial News

Quartet raises $17M series A

...Pfizer Venture Investment and Partners Innovation Fund also participated. Quartet is developing inhibitors of GTP cyclohydrolase 1 (GCH1...
BioCentury | Apr 22, 2010
Targets & Mechanisms

Promoting pain resolution

...of sepiapterin reductase (SPR) in lead development for neuropathic pain and an inhibitor of GTP cyclohydrolase 1 (GCH1...
BioCentury | Aug 1, 2008
Financial News

Sierra raises $21.5M

Sierra Neuropharmaceuticals ( Aurora , Colo.) raised $21.5 million in a series A round co-led by HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners. High Country Venture and GC&H Investments also participated. Sierra is reformulating drugs for...
BioCentury | Sep 27, 2007
Financial News

GlobeImmune raises $41.2 million

GlobeImmune (Louisville, Colo.) raised $41.2 million in a series C round led by Wexford Capital. Other new investors Celgene (CELG); Mellon Family Investment Company; Richard King Mellon Foundation; Eminent Venture Capital Corp.; Boston Life Science...
BioCentury | Jul 9, 2007
Emerging Company Profile

Solace: Comfort in (pain) research

...The ideas that PureTech turned into Solace include a preclinical series of GTP cyclohydrolase ( GCH1...
...that modulates glial cells that had completed Phase III testing in another, undisclosed indication. The GCH1...
...Research Group at Massachusetts General Hospital and Harvard Medical School. He discovered that the enzyme GCH1...
BioCentury | Sep 15, 2005
Financial News

GlobeImmune raises $34.3 million

Cancer and infectious disease company GlobeImmune (Denver, Colo.) raised $34.3 million in a series B round led by Lilly Ventures. New investors Medica Holdings; Adams Street Partners; Biogen Idec (BIIB); Genentech (DNA); Partners Healthcare; and...
Items per page:
1 - 10 of 14